Collaboration and education are critical to understanding and managing this mounting public health problem
Drug‐induced liver injury (DILI) is a major cause of acute liver failure, leading to liver transplantation and death,1 and it is one of the most frequent safety‐related causes of drug marketing withdrawals.2 DILI poses a growing challenge for clinicians, researchers, and regulatory bodies, with a vast array of new medications and herbal and dietary supplements constantly becoming available. Despite decades of experience with drug hepatotoxicity and the relatively recent development of clinical guidelines, registries, and other collaborative resources, much is still to be learned in this important field of medicine.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.